Dimethyl fumarate controlled-release - Forward Pharma

Drug Profile

Dimethyl fumarate controlled-release - Forward Pharma

Alternative Names: FP-187

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Forward Pharma
  • Developer Forward Pharma; Skane University Hospital
  • Class Anti-inflammatories; Antipsoriatics; Cytoprotectives; Esters; Fumarates; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Plaque psoriasis; Psoriatic arthritis
  • Preclinical Multiple sclerosis

Most Recent Events

  • 29 Nov 2017 Forward Pharma files further written submissions in the European Opposition Proceeding for the EP 2 801 355 patent with the Opposition Division of the European Patent Office
  • 31 May 2017 Forward Pharma challenges the decision by the PTAB in the patent interference lawsuit filed by Forward Pharma related to oral administration of dimethyl fumarate 480mg for Multiple sclerosis in USA
  • 18 Apr 2017 Dimethyl fumarate controlled-release is still in preclinical development for Multiple Sclerosis in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top